A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors

Nearly 100% of melanomas have a defect in the p16(INK4A):cyclin D-CDK4/6:RB pathway, leading to abnormal cell cycle control and unregulated cellular proliferation. Here, we report that P1446A-05, a novel multi-CDK inhibitor has significant inhibitory activity against cutaneous and uveal melanoma. Me...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Biol Ther
Egile Nagusiak: Eliades, Philip, Miller, David M., Miao, Benchun, Kumar, Raj, Taylor, Michael, Buch, Shama, Srinivasa, Sreesha P., Flaherty, Keith T., Tsao, Hensin
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2016
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4970529/
https://ncbi.nlm.nih.gov/pubmed/26810603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2016.1139267
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak